TCA
CLDX icon

Transcend Capital Advisors’s Celldex Therapeutics CLDX Stock Holding History

Transcend Capital Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Sell
6,196
-415
-6% -$13.4K 0.02% 727
2026
Q1 		$210K Sell
6,611
-2,626
-28% -$71.6K 0.02% 671
2025
Q4 		$251K Hold
9,237
– – 0.02% 587
2025
Q3 		$239K Buy
+9,237
New +$214K 0.02% 614

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Transcend Capital Advisors's CLDX Position: Q2 2026 in Review

Transcend Capital Advisors reduced its Celldex Therapeutics (CLDX) stake by 6.3% in Q2 2026, selling an estimated $13.4K and leaving 6,196 shares worth $231K. The position accounts for 0.02% of the portfolio, ranked #727.

Transcend Capital Advisors first reported a position in CLDX in Q3 2025 and has held it in 4 quarters since. The position peaked at $251K in Q4 2025. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Transcend Capital Advisors held 6,196 shares of Celldex Therapeutics worth $231K as of Q2 2026.
  • Transcend Capital Advisors sold 415 Celldex Therapeutics shares in Q2 2026, an estimated $13.4K.
  • Celldex Therapeutics made up 0.02% of Transcend Capital Advisors's portfolio in Q2 2026, its #727 holding.
  • Transcend Capital Advisors first reported a position in Celldex Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Transcend Capital Advisors's Celldex Therapeutics position peaked at $251K in Q4 2025.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Transcend Capital Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.